Astria Therapeutics, Inc. ( ATXS )

Derivative

Common Stock

263,321

-^{footnote F1}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F3}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

26,550

-^{footnote F3}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,166^{footnote F2}

-^{footnote F3}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

8,333

-^{footnote F3}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F3}

Footnote F1 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR
Footnote F2 (shares): These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
Footnote F3 (price): At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the… Full note on SEC EDGAR

Jan 23, 2026

Christopher Morabito - Officer

Derivative

Stock Option (Right to Buy)

80,000

-^{footnote F1}

Jan 23, 2026

Christopher Morabito - Officer

Derivative

Stock Option (Right to Buy)

262,500

-^{footnote F1}

Footnote F1 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR

Jan 23, 2026

Jill C. Milne - Officer

Derivative

Common Stock

4,377^{footnote F1}

-^{footnote F2}

Jan 23, 2026

Jill C. Milne - Officer

Derivative

Stock Option (Right to Buy)

195,000

-^{footnote F3}

Jan 23, 2026

Jill C. Milne - Officer

Derivative

Stock Option (Right to Buy)

761,000

-^{footnote F3}

Footnote F1 (shares): This number has been adjusted to reflect the 1-for-10 reverse stock split the Issuer effected on December 28, 2018 and the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
Footnote F2 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR
Footnote F3 (price): At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the… Full note on SEC EDGAR

Jan 23, 2026

Andrea Matthews - Officer

Derivative

Stock Option (Right to Buy)

32,812

-^{footnote F1}

Jan 23, 2026

Andrea Matthews - Officer

Derivative

Stock Option (Right to Buy)

20,000

-^{footnote F1}

Jan 23, 2026

Andrea Matthews - Officer

Derivative

Stock Option (Right to Buy)

262,500

-^{footnote F1}

Footnote F1 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

16,666^{footnote F1}

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

8,333

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

26,550

-^{footnote F2}

Footnote F1 (shares): These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
Footnote F2 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR

Jan 23, 2026

Andrew Komjathy - Officer

Derivative

Common Stock

-^{footnote F1}

Jan 23, 2026

Andrew Komjathy - Officer

Derivative

Common Stock

-^{footnote F1}

Jan 23, 2026

Andrew Komjathy - Officer

Derivative

Common Stock

-^{footnote F1}

Jan 23, 2026

Andrew Komjathy - Officer

Derivative

Stock Option (Right to Buy)

55,000

-^{footnote F4}

Jan 23, 2026

Andrew Komjathy - Officer

Derivative

Stock Option (Right to Buy)

225,000

-^{footnote F4}

Footnote F1 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR
Footnote F4 (price): At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the… Full note on SEC EDGAR

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

16,666^{footnote F1}

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

8,333

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

26,550

-^{footnote F2}

Footnote F1 (shares): These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
Footnote F2 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR

Jan 23, 2026

Benjamin Harshbarger - Officer

Derivative

Stock Option (Right to Buy)

33,333^{footnote F1}

-^{footnote F2}

Jan 23, 2026

Benjamin Harshbarger - Officer

Derivative

Stock Option (Right to Buy)

55,000

-^{footnote F2}

Jan 23, 2026

Benjamin Harshbarger - Officer

Derivative

Stock Option (Right to Buy)

262,500

-^{footnote F2}

Footnote F1 (shares): These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
Footnote F2 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

8,333

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

16,666^{footnote F1}

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

26,550

-^{footnote F2}

Footnote F1 (shares): These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
Footnote F2 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR

Jan 23, 2026

Noah Clauser - Officer

Derivative

Stock Option (Right to Buy)

55,000

-^{footnote F1}

Jan 23, 2026

Noah Clauser - Officer

Derivative

Stock Option (Right to Buy)

262,500

-^{footnote F1}

Footnote F1 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,166^{footnote F1}

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

8,333

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

26,550

-^{footnote F2}

Footnote F1 (shares): These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
Footnote F2 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

8,333

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

16,666^{footnote F1}

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

26,550

-^{footnote F2}

Footnote F1 (shares): These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
Footnote F2 (price): Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the… Full note on SEC EDGAR

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

16,666^{footnote F1}

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

8,333

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026

Derivative

Stock Option (Right to Buy)

14,100

-^{footnote F2}

Jan 23, 2026